What is Defence Therapeutics Inc. (DTC.CN) stock price today?

Defence Therapeutics Inc. (DTC.CN) is currently trading at $0.38, down 5% today.

What is DTC.CN P/E ratio?

Defence Therapeutics Inc.'s P/E ratio is -5.10. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is DTC.CN return on equity (ROE)?

Defence Therapeutics Inc.'s return on equity (ROE) is -232.79%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Defence Therapeutics Inc.'s market cap?

Defence Therapeutics Inc. has a market capitalization of $37.52M.

CNQ · —

Defence Therapeutics Inc. (DTC.CN) Stock

$0.38 -5.00% CNQ: DTC.CN —

—

Valuation

Metric	Value
Price	$0.38
Market Cap	$37.52M
P/E Ratio	-5.10
P/B Ratio	6.88
P/S Ratio	—
EPS (TTM)	$-0.10
52-Week High	$0.93
52-Week Low	$0.00
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-232.79%
ROA	-40.06%
ROCE	—
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.29
Current Ratio	3.37

Latest News

Rapid7, 8x8, Doximity, Marqeta, and Tenable Shares Are Soaring, What You Need To Know StockStory · Aug 16, 2026 Prediction: Nvidia Stock Will Fall After Aug. 26. Here Are 2 Reasons Why Motley Fool · Aug 16, 2026 Avocado pickers in Mexico welcome restart of exports to US, but security fears remain Associated Press · Aug 16, 2026 Why Leslie's (LESL) Stock Is Falling Today StockStory · Aug 16, 2026 Wesdome Gold Mines (TSX:WDO) Faces A 10% Fair Value Gap As Earnings Land Simply Wall St. · Aug 16, 2026

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	-9.90
FCF Yield	—
Quick Ratio	3.36
Interest Coverage	—
Return 1Y	-50.00%
Return 3Y	-83.94%
Return 5Y	-93.75%

Ownership

Insiders Held12.82%

Institutions Held0.00%

Institutions Float Held0.00%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BCT.TOBriaCell Therapeutics Corp.	$5.80	+0.00%	-4.25	$42.89M	0.00%
HBP.TOHelix BioPharma Corp.	$0.92	+0.00%	-45.00	$70.27M	0.00%
MDNA.TOMedicenna Therapeutics Corp.	$0.38	-7.32%	-2.09	$43.38M	0.00%
ONCO.NEOnco-Innovations Limited	$0.32	+3.23%	—	—	0.00%
RKV.VRakovina Therapeutics Inc.	$0.23	-8.00%	—	—	0.00%

About Defence Therapeutics Inc.

—

Defence Therapeutics Inc. is led by CEO Amie Phinney, employs 5 people, headquartered in Vancouver, CA, publicly traded since 2021.

Defence Therapeutics Inc. (DTC.CN) stock trades at $0.38 with a market capitalization of $37.52M. The stock is valued at a price-to-earnings (P/E) ratio of -5.10, price-to-book of 6.88. Over the past 52 weeks the stock has ranged between $0.00 and $0.93, and currently trades 59.1% below its 52-week high.

On profitability, Defence Therapeutics Inc. generates a return on equity (ROE) of -232.79%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: defencetherapeutics.com